6.02

0.66% -0.04

After Hours: 6.02

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is traded at $6.02, with a volume of 25,534. It is down -0.66% in the last 24 hours and down -13.75% over the past month. Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Previous Close:

$6.06

Open:

$6.3

24h Volume:

25,534

Relative Volume:

0.25

Market Cap:

$103.42M

Revenue:

$35.58M

Net Income/Loss:

$-17.89M

P/E Ratio:

-8.8231

EPS:

-0.6823

Net Cash Flow:

$-17.74M

1W Performance:

+7.69%

1M Performance:

-13.75%

6M Performance:

-10.28%

1Y Performance:

-1.59%

1-Day Range:

$6.01

$6.30

1-Week Range:

$5.48

$6.30

52-Week Range:

$3.28

$9.8212

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

484-453-3300

Address

44 WEST GAY STREET, WEST CHESTER, PA

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

VRCA's Discussions on Twitter

Compare VRCA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRCA Verrica Pharmaceuticals Inc	6.02	104.10M	35.58M	-17.89M	-17.74M	-0.6823
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

08:07 AM

VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus

08:07 AM

May 23, 2026

Number of shareholders of Verrica Pharmaceuticals Inc. – LSX:A41A98 - TradingView

May 23, 2026

May 22, 2026

Verrica Expands YCANTH Sales as Wart Trials Advance - MyChesCo

May 22, 2026

May 19, 2026

Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

May 19, 2026

Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

May 19, 2026

May 16, 2026

Earnings call transcript: Verrica Pharmaceuticals Q1 2026 shows revenue growth - Investing.com Nigeria

May 16, 2026

Verrica Pharmaceuticals Q1 earnings call highlights - MSN

May 16, 2026

May 15, 2026

VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill

May 15, 2026

May 14, 2026